Bangladesh · Delayed Price · Currency is BDT Techno Drugs Statistics
Total Valuation
Techno Drugs has a market cap or net worth of BDT 5.62 billion. The enterprise value is 8.40 billion.
| Market Cap | 5.62B |
| Enterprise Value | 8.40B |
Important Dates
The next estimated earnings date is Sunday, November 1, 2026.
| Earnings Date | Nov 1, 2026 |
| Ex-Dividend Date | Nov 20, 2025 |
Share Statistics
Techno Drugs has 132.00 million shares outstanding. The number of shares has increased by 6.83% in one year.
| Current Share Class | 132.00M |
| Shares Outstanding | 132.00M |
| Shares Change (YoY) | +6.83% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 62.72% |
| Owned by Institutions (%) | n/a |
| Float | 49.21M |
Valuation Ratios
The trailing PE ratio is 27.78.
| PE Ratio | 27.78 |
| Forward PE | n/a |
| PS Ratio | 1.81 |
| PB Ratio | 1.36 |
| P/TBV Ratio | 1.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 14.65 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 41.51 |
| EV / Sales | 2.71 |
| EV / EBITDA | 7.87 |
| EV / EBIT | 12.16 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.27, with a Debt / Equity ratio of 0.68.
| Current Ratio | 3.27 |
| Quick Ratio | 1.37 |
| Debt / Equity | 0.68 |
| Debt / EBITDA | 2.64 |
| Debt / FCF | -6.56 |
| Interest Coverage | 1.62 |
Financial Efficiency
Return on equity (ROE) is 4.98% and return on invested capital (ROIC) is 7.87%.
| Return on Equity (ROE) | 4.98% |
| Return on Assets (ROA) | 5.77% |
| Return on Invested Capital (ROIC) | 7.87% |
| Return on Capital Employed (ROCE) | 10.22% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 2.16M |
| Profits Per Employee | 140,756 |
| Employee Count | 1,438 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 1.67 |
Taxes
In the past 12 months, Techno Drugs has paid 62.70 million in taxes.
| Income Tax | 62.70M |
| Effective Tax Rate | 23.65% |
Stock Price Statistics
The stock price has increased by +51.06% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +51.06% |
| 50-Day Moving Average | 39.37 |
| 200-Day Moving Average | 34.01 |
| Relative Strength Index (RSI) | 52.67 |
| Average Volume (20 Days) | 2,848,761 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Techno Drugs had revenue of BDT 3.10 billion and earned 202.41 million in profits. Earnings per share was 1.53.
| Revenue | 3.10B |
| Gross Profit | 1.35B |
| Operating Income | 690.76M |
| Pretax Income | 265.11M |
| Net Income | 202.41M |
| EBITDA | 1.07B |
| EBIT | 690.76M |
| Earnings Per Share (EPS) | 1.53 |
Balance Sheet
The company has 38.46 million in cash and 2.82 billion in debt, with a net cash position of -2.78 billion or -21.06 per share.
| Cash & Cash Equivalents | 38.46M |
| Total Debt | 2.82B |
| Net Cash | -2.78B |
| Net Cash Per Share | -21.06 |
| Equity (Book Value) | 4.14B |
| Book Value Per Share | 31.38 |
| Working Capital | 1.99B |
Cash Flow
In the last 12 months, operating cash flow was 383.71 million and capital expenditures -813.23 million, giving a free cash flow of -429.52 million.
| Operating Cash Flow | 383.71M |
| Capital Expenditures | -813.23M |
| Depreciation & Amortization | 377.22M |
| Net Borrowing | 117.68M |
| Free Cash Flow | -429.52M |
| FCF Per Share | -3.25 |
Margins
Gross margin is 43.66%, with operating and profit margins of 22.27% and 6.53%.
| Gross Margin | 43.66% |
| Operating Margin | 22.27% |
| Pretax Margin | 8.55% |
| Profit Margin | 6.53% |
| EBITDA Margin | 34.43% |
| EBIT Margin | 22.27% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 2.29%.
| Dividend Per Share | 1.00 |
| Dividend Yield | 2.29% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 21.17% |
| Buyback Yield | -6.83% |
| Shareholder Yield | -4.58% |
| Earnings Yield | 3.60% |
| FCF Yield | -7.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |